Rapidly-growing Mycobacterium Susceptibility−Broth Dilution
Also known as: M abscessus Susceptibility Testing, M chelonae Susceptibility Testing, M fortuitum Complex Susceptibility Testing, AFB Susceptibility Testing, Rapid-grower Susceptibility Testing
Use
Determine the susceptibility of rapidly-growing mycobacterial isolates to a profile of antimycobacterial agents. If cultures remain positive after 6 months of treatment, repeat susceptibility testing is recommended.
Special Instructions
Not provided.
Limitations
Susceptibilities cannot be reported if the organism fails to grow in the test medium. The test cannot be performed on mixed cultures and requires organism identification prior to reporting susceptibility results. There are no established interpretive criteria for tigecycline and clofazimine due to insufficient clinical data, and certain susceptibility results such as those for imipenem are not predictive for similar drugs such as meropenem due to differences in activity against rapidly growing mycobacteria.
Methodology
Culture-based
Biomarkers
LOINC Codes
- 40699-1 - Mycobacterium Spec
- 5-Dec
- 116-4 - cefOXitin Islt MIC
- 185-9 - Ciprofloxacin Islt MIC
- 189-1 - Clarithro Islt MIC
- 16623-1 - Clofazimine Islt MIC
- 225-3 - Doxycycline Islt MIC
- 279-0 - Imipenem Islt MIC
- 29254-0 - Linezolid Islt MIC
- 31037-5 - Moxifloxacin Islt MIC
- 42355-8 - Tigecycline Islt MIC
- 508-2 - Tobramycin Islt MIC
- 516-5 - TMP SMX Islt MIC
Result Turnaround Time
20-35 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Not provided
Minimum Volume
1 mL
Container
Conventional or broth medium, tightly sealed, in etiologic agent packaging
Storage Instructions
Maintain media at room temperature.
Causes for Rejection
Specimen received in leaking or in broken transport tube or vial; specimen received in expired transport medium; mixed culture; unlabeled culture or name discrepancy between specimen and request label
Other tests from different labs that may be relevant